Asundexian Associated with an Impressive 26% Reduction in Recurrent Stroke Without Increased Bleeding. The OCEANIC-STROKE trial
Asundexian is a direct, potent small molecule inhibitor of Factor XIa (FXIa).…
NOAC Monotherapy Non-Inferior to Combination Therapy for Net Adverse Clinical events in AF Patients Post–DES: ADAPT AF-DES Trial
Key Points The ADAPT AF-DES randomized trial compared NOAC monotherapy (apixaban or…
Prasugrel Might be a Better Choice than Ticagrelor For DAPT after PCI for Patients with Diabetes and MVD: The TUXEDO-2 Trial
Key Points TUXEDO-2 directly compared ticagrelor vs prasugrel based DAPT in 1,800…
Two Factor XI Antibodies For the Prevention of Post- operative VTE: Results from ROXI-VTE-I and ROXI-VTE-II Trials
Key Points: ROXI-VTE-I and ROXI-VTE-II evaluated two distinct factor XI monoclonal antibodies…
Dapagliflozin Reduced LVMI in Patients with CKD : DECODE-CKD
Key Points The DECODE-CKD trial investigated the effects of SGLT-2 inhibitor Dapagliflozin…
Benefit from Intensive BP Control Across Frailty Statuses – A Post-Hoc Analysis of ESPRIT trial
Key Points The ESPRIT trial assessed whether the efficacy and safety of…